948897-66-3

Upstream product

• 909543-30-2 (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid 
• 104-15-4 toluene-4-sulfonic acid 
• 948897-70-9 C₇H₈O₃S*C₂₁H₁₆Cl₂N₂O₃ 
• 65515-28-8 methyl 2,6-dichloronicotinate 
• 2100-42-7 2-chloro-1,4-dimethoxybenzene 
• 948897-63-0 C₂₁H₁₇Cl₂NO₄ 
• 948897-62-9 C₂₃H₂₁Cl₂NO₄ 
• 925207-28-9 methyl 6-(4-chloro-phenoxy)-2-propylnicotinate 
• 948897-61-8 C₁₅H₁₄ClNO₃ 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 906794-87-4 methyl 2-chloro-6-(4-chlorophenoxy)nicotinate 

Relevant academic research and scientific papers

NOVEL CRYSTALLINE SALT FORM OF AN ANTIDIABETIC COMPOUND

A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for

NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS

A novel crystalline anhydrate of the free acid and a crystalline anhydrous besylate salt of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety are stable and non-hygroscopic. The compou